war schon ein langer Weg vom S-1 vom 13.11.2006 über die vielen amends bis zum 424B3 vom 30.05.2007
http://www.sec.gov/cgi-bin/...lenum=333-138632&owner=include&count=40
hier aus dem 424B3 vom 30.05.2007
http://www.sec.gov/Archives/edgar/data/1084000/...7029395/v077044.txt
24,591,491 Shares
BIOPHAN TECHNOLOGIES, INC.
COMMON STOCK
This prospectus relates to 24,591,491 shares of our common stock that may
be sold from time to time by the selling stockholders named herein.
....
THE OFFERING
Common stock offered by the
selling stockholders 24,591,491 shares
Common stock to be outstanding
after this offering 108,023,190*
Use of proceeds We will not receive any proceeds from the
sale of shares by the selling stockholders.
Risk factors You should read the "Risk Factors" section
of this prospectus for a discussion of
factors that you should consider carefully
before deciding to invest in shares of our
common stock.
OTC Bulletin Board symbol "BIPH"
The number of shares of our common stock to be outstanding following this
offering is based on 83,431,699 shares of our common stock outstanding as of
May 18, 2007, and assumes (i) the conversion of an aggregate face amount of
$7,250,000 of our outstanding Senior Secured Convertible Notes due October 11,
2009 into an aggregate of 10,820,896 shares of common stock to be sold by
selling stockholders in this offering, (ii) the exercise of warrants to purchase
an aggregate of 11,686,568 shares of common stock to be sold by selling
stockholders in this offering, and (iii) the issuance of an aggregate of
2,084,027 shares of common stock in payment of interest to accrue under the
Notes during their term, and to be sold by the selling stockholders in this
offering, and excludes (i) the exercise of outstanding options under our
incentive stock compensation plans, (ii) the issuance of any shares of our
common stock to SBI Brightline XI, LLC pursuant to the Stock Purchase Agreement
dated as of May 27, 2005 (as amended), and (iii) the exercise of any other
options, warrants or other rights to acquire shares of our common stock by any
person or entity (including the selling stockholders).
* Includes 4,923,080 shares of our common stock held by Myotech, LLC, an
entity of which we are a 43.7% beneficial owner. Because we consolidate our
financial statements with those of Myotech in accordance with FASB
Interpretation No. 46 (Revised December 2003), "Consolidation of Variable
Interest Entities" ("FIN 46(R)"), these shares are carried as treasury shares on
our Consolidated Balance Sheets and Consolidated Statements of Stockholders'
Equity. However, because we do not have direct control over the voting or
disposition of the shares held by Myotech, these shares are treated as issued
and outstanding shares throughout this prospectus except (i) in the section
entitled "Selected Financial Data" on page 10 and (ii) in the Financial
Statements beginning on page F-1.
.....
beim Suchen nach Antworten bin ich nochmal zur sec-Seite gelangt
http://www.sec.gov/cgi-bin/...biophan&owner=include&action=getcompany
ist schon interessant, den langen Weg nachzuvollziehen (neu eingespielt, die intensive Korrespondenz)
weiter bin ich mit meinen Gedanken immer noch nicht gekommen - eins scheint aber sicher zu sein, dieses 424B3 hat einen langen Weg gehabt - Zeit in der es ordentlich abwärts ging - mal sehen, wie es weiter geht??
|
Thread abonnieren
